# Edwards Lifesciences Stock Innovates Ahead of Q3 Results

> Edwards Lifesciences stock shows strength with recent FDA approvals and a growing cardiology portfolio.
- Title: Edwards Lifesciences Stock Innovates Ahead of Q3 Results
- Summary: Edwards Lifesciences stock shows strength with recent FDA approvals and a growing cardiology portfolio. Edwards Lifesciences stock remains a buy with strong…
- Keywords: edwards lifesciences, fda, cardiology, q3 results, stock, nyse, money, business, Edwards, Lifesciences, Innovates, Ahead
- Source: Seekingalpha — https://seekingalpha.com/article/4959061-edwards-lifesciences-stock-continually-innovating-q3-earnings-cardio-portfolio-thrives
- Author: Albert Anthony
- Published: 2026-10-29T11:30:15+00:00
- Read time: 1 min
- Topics: edwards lifesciences, fda, cardiology, q3 results, stock, nyse, ew, money, business
## Edwards Lifesciences Stock
Edwards Lifesciences gets a buy rating with recent FDA approvals and a niche cardiology portfolio.
## Market Cap and FDA Approval
Over $51 billion market cap with recent FDA approval for cardiology products.
## Author Background
Albert Anthony is a business author with 2,020 followers on Seeking Alpha since 2023.
## Author Credentials
Albert Anthony has a B.A. from Drew University and certifications from Microsoft, CompTIA, and Corporate Finance Institute.
## Author Disclosure
Albert Anthony has no stock positions in any companies mentioned and writes independently.
## Seeking Alpha Disclosure
Seeking Alpha states past performance is not a guarantee of future results and no investment advice is given.
## Key takeaway

Edwards Lifesciences stock remains a buy with strong FDA approvals and a niche cardiology portfolio driving growth.